Published in Haematologica on March 05, 2008
Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood (2008) 1.69
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68
The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program (2009) 1.62
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res (2009) 1.29
Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer (2009) 1.25
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood (2009) 1.23
Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol (2012) 1.17
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther (2012) 1.09
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol (2009) 1.04
Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. Haematologica (2008) 1.00
Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat (2008) 0.94
New Approaches to Target T-ALL. Front Oncol (2014) 0.88
Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol (2010) 0.88
Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget (2016) 0.87
JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. Haematologica (2009) 0.85
Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner. Apoptosis (2014) 0.78
Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL. PLoS One (2015) 0.77
Apoptotic role of IKK in T-ALL therapeutic response. Mol Cancer Res (2011) 0.76
The protective role of parsley extract against vincristine mutagenicity in Drosophila melanogaster. Saudi J Biol Sci (2010) 0.75
New flow cytometry in hematologic malignancies. Haematologica (2009) 0.75
Activation of the NOTCH1 pathway in chronic lymphocytic leukemia. Haematologica (2012) 0.75
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell (2008) 5.40
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet (2005) 3.87
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol (2008) 3.45
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet (2012) 2.64
Amplification of the pressure pulse in the upper limb in healthy, middle-aged men and women. Hypertension (2009) 2.59
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res (2007) 2.41
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 2.14
Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma (2008) 2.12
Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet (2006) 2.11
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem (2005) 2.05
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet (2011) 1.99
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92
A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol (2009) 1.84
Nonrecurrent MECP2 duplications mediated by genomic architecture-driven DNA breaks and break-induced replication repair. Genome Res (2008) 1.81
Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation. Am J Hum Genet (2008) 1.80
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res (2004) 1.79
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes. Hum Mutat (2007) 1.79
Atonal homolog 1 is a tumor suppressor gene. PLoS Biol (2009) 1.76
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med (2008) 1.70
Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res (2008) 1.69
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2002) 1.65
External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist (2011) 1.59
Paternal age at birth is an important determinant of offspring telomere length. Hum Mol Genet (2007) 1.58
NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal Chem (2008) 1.53
The dark side of EGFP: defective polyubiquitination. PLoS One (2006) 1.49
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood (2003) 1.47
X chromosome array-CGH for the identification of novel X-linked mental retardation genes. Eur J Med Genet (2005) 1.47
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res (2008) 1.46
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res (2012) 1.44
Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia. Cancer Res (2002) 1.44
Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica (2005) 1.43
CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Mol Genet (2003) 1.43
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A (2006) 1.40
Evidence for increased SOX3 dosage as a risk factor for X-linked hypopituitarism and neural tube defects. Am J Med Genet A (2014) 1.39
Deletion of VCX-A due to NAHR plays a major role in the occurrence of mental retardation in patients with X-linked ichthyosis. Hum Mol Genet (2005) 1.37
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest (2006) 1.35
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res (2006) 1.34
Molecular diagnostics for congenital hearing loss including 15 deafness genes using a next generation sequencing platform. BMC Med Genomics (2012) 1.32
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest (2007) 1.30